Company news
Valeo Pharma Inc. news in 2022
Valeo Pharma Inc.'s news releases, calls and decks from 2022, newest first.
Valeo Pharma announces senior management change
November 21, 2022
Valeo Pharma raises Q4 and full year 2022 revenue guidance
November 15, 2022
Valeo Pharma enters into Canadian commercial services agreement with Veru for sabizabulin in hospitalized adult patients with COVID-19 at high risk for acute respiratory distress syndrome (ARDS)
September 14, 2022
Valeo Pharma reports record third quarter 2022 results and Highlights
September 13, 2022
Valeo Pharma to host third quarter 2022 results conference call / webcast
September 9, 2022
Valeo Pharma adds pharmaceutical industry veteran Kyle Steiger to leadership team
August 30, 2022
Valeo Pharma closes US$40 million non-dilutive financing from Sagard Healthcare Partners
August 2, 2022
Valeo Pharma enters into license agreement with Kaléo for the Canadian rights to ALLERJECT®
August 2, 2022
Valeo Pharma enters into an agreement for ophthalmic products, prxiidra® and prsimbrinza®, in Canada
August 2, 2022
Valeo Pharma reports its second quarter 2022 results and highlights
June 14, 2022
Valeo Pharma to host second quarter 2022 results conference call / webcast
June 8, 2022
Valeo Pharma announces results of annual meeting of shareholders, appointments and options and rsu grants
April 28, 2022
Valeo Pharma to present at the 2022 bloom burton & co healthcare investor conference
April 25, 2022
Valeo Pharma announces listing of convertible debentures on TSX
April 19, 2022
Valeo Pharma announces listing to the toronto stock exchange
March 28, 2022
Valeo Pharma reports its first quarter 2022 results and highlights
March 24, 2022
Valeo Pharma secures additional public reimbursement for Redesca™, Enerzair® Breezhaler® and Atectura® Breezhaler®
March 22, 2022
Valeo Pharma to host first quarter 2022 results conference call / webcast and attend the 8th annual AlphaNorth capital conference
March 17, 2022
Valeo Pharma reports record annual revenues for fiscal 2021
February 28, 2022
Valeo Pharma obtains public reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Ontario, Manitoba and New Brunswick
February 24, 2022
Valeo Pharma to host fourth quarter and year-end 2021 results conference call / webcast
February 21, 2022
Valeo Pharma's Hesperco™ now available at Loblaws, hesperidin COVID-19 clinical trial results submitted for publication
January 5, 2022
Decks in 2022
- Investor Presentation (November 2022)
Investor deck · 28 slides · November 2022